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Active screening for resistant multidrug strain carriers remains an important component of infection control policy in any
healthcare setting indifferent of financial and logistical costs. The objective of our study was to determine the spectrum of bacterial
colonization individually among intensive care unit patients. A retrospective observational study was performed in the Intensive
Care Unit of Emergency Clinical CountyHospital of Oradea during 2017.Medical records of the patients were used for evaluation of
source of ICU admission, previous antibiotic therapy, comorbidities, and length of hospital stay. Nasal and groin swabs for MRSA
detection and rectal swabs for ESBL, VRE, and CRE detection were collected upon ICU admission of all patients in the first 24
hours and after 7 days. Swab samples were processed for isolation and identification of these resistant multidrug strains. Bacterial
colonization on admission was detected in a quarter of patients included in the study. Carbapenemase-producing bacteria were
the most common colonizers (21.16%). On admission, 12.06% of patients have been colonized by ESBL-producing members of
the family Enterobacterales. Risk factors for colonization on admission to the ICU were chronic liver diseases and chronic renal
failure for ESBL infection and chronic liver disease for CRE inmale patients. Evaluation of Carmeli’s score for male patients showed
association only with CRE colonization. Chronic renal failure was found as risk factor for ESBL colonization in female patients.
The prevalence of MRSA was 5.23% and less than 1% for VRE. There was no association between any risk factors studied and the
presence of S. aureus or VRE upon admission. The 7-day ICU stay also proved to be an increased risk for ESBL and CRE infection.
1. Introduction
Infections associated with medical care (nosocomial) repre-
sent a worldwide problem despite the advancement in ther-
apeutic technologies [1]. Intensive care unit (ICU) patients
are more affected by these infections caused by special
pathogens contributing to prolonged intensive care unit stays,
increased morbidity and mortality, and increased resource
utilization. Special interest is directed at the study of these
special microorganisms resistant to multiple antimicrobials,
Hindawi
BioMed Research International
Volume 2019, Article ID 2510875, 9 pages
https://doi.org/10.1155/2019/2510875
2 BioMed Research International
which are growing at higher rate in the ICU setting, leading
to higher treatment costs, morbidity, and mortality [2–6].
An important risk factor for nosocomial infection is prior
colonization [7, 8]. Other clinical reports show different
data about the incidence and patterns of colonization of
multidrug-resistant bacteria [9–11].
As a definition, multiple drug resistance (MDR) is non-
susceptibility of a strain to at least one agent in three or more
antibiotic classes [12]. In ICUs, the identified multidrug-
resistant microorganisms include both Gram-positive bac-
teria (Staphylococcus aureus and Enterococcus spp.) and
Gram-negative bacilli (Escherichia coli, Acinetobacter bau-
mannii, Pseudomonas aeruginosa, Proteus spp., and Klebsiella
spp.). Methicillin-resistant Staphylococcus aureus (MRSA),
vancomycin-resistant Enterococcus spp. (VRE), extended-
spectrum beta-lactamase producers (ESBL), carbapenemase-
resistant Enterobacteriaceae (CRE), and multidrug-resistant
Gram-negative bacteria (MDR) are well described [13–16].
MRSA could be a major cause of severe nosocomial infec-
tions (bloodstream infections, urinary tract infections, and
pneumonia) contributing to the high mortality because of
its resistance to a variety of antibiotics [17]. Vancomycin-
resistantEnterococcus (VRE) has the same difficulties in treat-
ing infections or colonization [18]. Gram-negative organisms
are important causes of the same nosocomial infections [19,
20]. ESBL Gram-negative producers are frequently isolated
especially in ICU patients with multiple comorbidities and
they are associated with high morbidity and mortality, due
to the limited therapeutic options [21]. The narrowing of
treatment strategies and the limited availability of future
underdevelopment drugs lead to spreading of MDR-GN
bacterial infections [22, 23]. In recent years, Food and
Drug Administration (FDA) has approved the usage of new
antibiotic combinations such as ceftolozane/tazobactam and
ceftazidime/avibactam that are proven to be effective against
MDR-GN, but the emergence of resistant strains is just a
matter of time [16, 24]. Antibiotic resistance was discovered
with the discovery of antibiotics, and a significant number
of the analysed strains isolated from food products showed
resistance to different antibiotic classes and the molecular
techniques revealed that many of these possess either one or
multiple genes that confer resistance to different antibiotics,
like presence of ESBL and AmpC production [19, 25].
Bacterial colonization of the skin and mucous mem-
branes of patients with these microorganisms usually pre-
cedes infections. Colonizers are part of the commensal
bacterial flora of the skin that protects it from colonization
with pathogenic bacteria; therefore they do not cause any
problems usually. These different colonies may disappear
spontaneously or be cleared under the action of disinfec-
tant and antimicrobial agents. However, they can also turn
into pathogenic bacteria if the activity of the skin surface
antimicrobial proteins (AMPs) is compromised or the strains
acquire new genes that modify the disease-producing capac-
ity of the bacteria [26, 27]. When the protective barriers of
skin and mucous membranes are compromised or immunity
deficiency develops, these organisms overwhelm the body,
resulting in an infection [28]. Screening of ICU patients
upon admission for colonization by MDR strains, handling
them with caution and isolation of colonized patients, could
prevent nosocomial infections [29]. The purpose of this
screening is to prevent spreading of these organisms to other
ICU/non-ICU patients, especially those vulnerable to drastic
consequences in case of transmission. A study reported
that the screening of ICU patients upon admittance for the
presence of MRSA and VRE despite special measures applied
to isolate carriers did not result in a reduction of ICU-
acquired infection with the aforementioned pathogens [29].
Instead, a recent review of literature published by Glick et
al. implies that screening to universal MRSA carriage upon
admission may reduce the risk of MRSA infections but the
power of evidence was weak to support screening programs
[30].
There are several scoring system models in use to esti-
mate the severity of critical illness and to predict mortality
among ICU patients. The acute physiology and chronic
health evaluation (APACHE) model was first introduced,
followedbyAPACHE II andAPACHE III including data from
American hospitals [31]. Another model, the simplified acute
physiology score (SAPS), was instituted in 1985, followed by
the revised editions SAPS II and SAPS III as an alternative
to the APACHE score. SAPS I is employing 14 of the original
34 parameters used in the APACHE system and SAPS II and
SAPS III included data of 12 parameters from the first 24
hours in the ICU [32–34].
In patients who have severe comorbidities and/or are
immunocompromised, the multiple hospitalizations and the
long-term antibiotic therapy sometimes in combination rep-
resent a high risk in the selection and the colonization
and infection with resistant or multidrug-resistant strains
[35]. The expected chance with which the bacteria might be
resistant to the antimicrobial treatment can be assessed using
Carmeli’s score [36–38].
This study was undertaken to evaluate the prevalence and
the spectrum of bacterial colonization in patients admitted
to the ICU of the Emergency Clinical County Hospital
of Oradea, and to assess the predisposing risk factors for
colonization.
2. Materials and Methods
2.1. Data Collection. The study was conducted at Emergency
Clinical County Hospital of Oradea, with a 45-bed ICU
that receives patients from within the hospital as well as
ones referred from outside. It manages approximately 5600
critically ill patients annually. After ethical clearance by the
institution and after receiving informed consent from the
patient or from the next of kin (in case of unconscious
patient), an active surveillance of 1971 adult admitted patients
was done between January and December 2017.
Demographic characteristics, source of ICU admission,
previous hospitalization, previous antibiotic therapy, comor-
bidities, length of hospital stay, and outcome were recorded
and analysed. In order to identify the risk factors for col-
onization with multidrug-resistant strains, the diagnostics
have been grouped and analysed as follows: respiratory
(pneumonia, bronchial asthma, and chronic obstructive
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pulmonary disease) and cardiovascular diseases (hyperten-
sion, myocardial infarction, chronic heart failure, coronary
heart disease, chronic atrial fibrillation, and stroke), chronic
renal failure and diabetic nephropathy, chronic liver diseases
(chronic hepatitis, hepatic cirrhosis, hepatic encephalopa-
thy, and chronic hepatic insufficiency), cancer, hematologic
malignancy (lymphoma and leukaemia), immunosuppres-
sive status (chronic obstructive pulmonary disease, organ
transplant, chronic autoimmune diseases, and AIDS), and
diabetes mellitus.
Medical history of the patients, results of physical exam-
ination, and multiple laboratory parameters were analysed
to calculate Carmeli’s score in order to identify patients
susceptible to be colonized with multidrug-resistant bacteria
at the beginning of the hospitalization. The scoring and
stratification were based upon the presence of Carmeli’s risk
factors [36, 37]. Risk factors were ranked with 1, 2, or 3 points
according to the prediction for infection with susceptible,
resistant, or multidrug-resistant microorganisms. Patients
were scored as 1 to 3 according to the severity of the
following factors: the degree of contact with the healthcare
system and invasive procedures; antibiotic treatment; and
patient characteristics such as age, various comorbidities, or
immunosuppressed status. The highest numeric value of the
three criteria represents final value of Carmeli’s score (1, 2, or
3). The final score allowed us to classify patients as follows:
score 1 (community-acquired infections with microorgan-
isms susceptible to classic antibiotics), score 2 (probably
healthcare-associated or community-acquired infections but
with high probability of resistant or multidrug-resistant
strains), and score 3 (maximum prediction for nosocomial
infections with resistant or multidrug-resistant strains) [38].
2.2. Microbiological Procedures. Nasal, groin, and/or rectal
swab samples were collected to assess bacterial colonization
during the first 24 hours of ICU admission from all study
participants. The same samples were collected 7 days after
admission for patients who remained hospitalized for that
time period. Nasal and respective groin swab samples were
collected by wiping the swab in circular motion while
simultaneously rotating it in 360∘ and exerting gentle pressure
on the surface. Rectal samples were collected by inserting the
swab 1 cm into the rectum while rotating the swab in 360∘.
Swabs collected were placed in sterile round bottom tubes
containing 1ml sterile Amies transport medium and imme-
diately transferred to the laboratory for analysis. Collected
nasal and groin sampleswere screened forMRSA,while rectal
swabs were screened for VRE, ESBL, and/or CRE.The strains
have been considered multidrug-resistant if they displayed
resistance to more than three antibiotic classes. Patients were
considered to be colonized by any of the organisms studied if
one or more of those organisms was/were isolated from one
or more of the swabbed sites.
2.2.1. MRSA. Nasal and groin samples collected were
cultured on MRSA CHROMagar (CHROMID MRSA,
bioMe´rieux) and incubated at 37∘C for 24 hours. Plates
were examined for green MRSA colonies; other colours were
disregarded. In addition, the latex agglutination test was
performed to identify penicillin-binding protein, PBP2A.The
isolates were confirmed as MRSA by disc diffusion test using
30 𝜇g cefoxitin disc on Mueller-Hinton agar according to
EuropeanCommittee onAntimicrobial Susceptibility Testing
(EUCAST) guidelines. Quality control was done by using
Staphylococcus aureus ATCC 25923.
2.2.2. VRE. Rectal swab samples were cultured on selective
chromogenic medium (CHROMID VRE) for direct iden-
tification of E. faecalis and E. faecium. The medium allowed
the detection of acquired vancomycin-resistant strains (vanA
and vanB) by selective coloration of the colonies as follows:
blue-green for E. faecalis and violet for E. faecium. For quality
control E. faecalis ATCC 51299 was used.
2.2.3. ESBL. All the rectal swabs were processed for isolation
of ESBL-producing GN bacteria. Gram-negative bacteria
were isolated on ESBL chrome agar (CHROMID ESBL,
bioMe´rieux). After incubation for 24 hours, it is easy to
read results based on the specific coloration. Escherichia
coli shows a pink to burgundy coloration (ß-glucuronidase-
producing colonies), Klebsiella, Enterobacter, Serratia, and
Citrobacter display a green/blue to brownish green coloration
(ß-glucosidase-producing colonies), Proteus, Providencia,
and Morganella appear in dark to light brown colonies
(deaminase-expressing strains), andAcinetobacter spp. shows
a cream coloration. ESBL producers were confirmed phe-
notypically by the double-disk synergy test using clavulanic
acid and third-generation cephalosporins. Disks of third-
generation cephalosporins and amoxicillin-clavulanic acid
were kept 15–20 mm apart, centre to centre, on inoculated
Mueller-Hinton agar.The plates were incubated at 35∘C–37∘C
for 18–24 hours. A clear extension of the edge of the
inhibition zone of any of the third-generation cephalosporins
towards the amoxicillin-clavulanic acid disk was interpreted
as positive for ESBL production. Escherichia coliATCC 25922
was used for quality control.
2.2.4. CRE. The rectal swabs were analysed as well for the
presence of GN bacteria with a reduced susceptibility tomost
of the carbapenem agents. We used selective chromogenic
medium for the screening of carbapenemase-producing
Enterobacteriaceae (CHROMID CARBA). Escherichia coli
displays a pink to burgundy coloration, Klebsiella shows
green coloration, and Acinetobacter spp. appears in colorless
or cream colonies. Any carbapenem-resistant isolate was
investigated for phenotypic carbapenemase production using
the carbapenem inhibition method [39]. For quality control,
Klebsiella pneumoniae ATCC 25955 was used.
All isolates were identified to the species level by using
MALDI-TOF mass spectrometry. The antibiotic susceptibil-
ity pattern was obtained by the Kirby–Bauer disc diffusion
methodonMueller–Hinton agar andVitek-2 according to the
EUCAST guidelines.
Patients were considered colonized by any of the organ-
isms studied if one or more of those organisms were isolated
from at least one of the swabbed sites. ICU-acquired infection
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Table 1: Clinical characteristics of the patients (n= 1971).
Male Female
Number of patients 1107 864
Mean age (years) 65.13±14.65 70.15±14.13
Age > 65 years 599 618
Carmeli score 1.54±0.66 1.75±0.77
Previous hospitalization 349 274
Antibiotic treatment 825 648
Surgical patients 53 42
Perioperative infection prophylaxis 13 10
Respiratory diseases 173 140
Cardiovascular diseases 516 437
Chronic renal failure 30 14
Chronic liver diseases 47 27
Cancer 96 70
Hematologic malignancy 3 0
Diabetes mellitus 183 210
was defined if any of the studied pathogen colonies were
detected 7 days after ICU admission in previously negative
patients.
2.3. Data Analysis. Data were described as mean ± standard
deviation (SD), number of cases, or percentages where
appropriate. For the statistical analysis of the contingency
tables, Chi-square test and Fisher’s exact test were used.
Statistical significance was considered when p<0.05. All
statistical calculations were done with GraphPad Prism 7.00.
3. Results
3.1. Demographic Data of Patients. The demographic char-
acteristics and the possible risk factors for infection are
summarized in Table 1. A total of 1971 patients, 1107males and
864 females, were included in this study. The male : female
ratio was 1.28 : 1 (56.16% male and 43.83% female). Mean age
range was 65.13±14.65 years for males and 70.15±14.13 for
females. More than half of the patients were above 65 years
of age. One-third of patients (31.6%) had been hospitalized in
the previous months, 1473 of 1971 (74.73 %) have been treated
with antibiotics, and 44 (2.23%) patients with chronic renal
failure came in for regular dialysis.
Carmeli’s score was an average of 1.54±0.66 in the male
and 1.75±0.77 in female patients. The interpretation of our
results shows that the patients included in the study are
mostly with probably healthcare-associated or community-
acquired infections but with high probability of resistant or
multidrug-resistant strains. Among our patients, 96 (4.87%)
were surgical patients, from whom 23 (23.95%) received
a perioperative infection prophylaxis; therefore the rest of
the patients were medical patients and the majority had
received at least one group of antibiotics. The main three
chronic disease groups presented by patients included in
the study were cardiovascular disease, diabetes mellitus, and
respiratory diseases regardless of the gender.
3.2. Bacterial Pattern of Colonization upon Admission. Over-
all, 1971 patients were sampled at one or more sites (nasal,
groin, and rectal region) to assess colonization. Bacterial
colonization (of 1 ormore sites) upon admission was detected
in 494 patients (25.06%). Evaluation of spectrum of bacterial
colonization on admission shows that there are no significant
differences between male and female patients. The results
of the cultures from different swabbed sites obtained from
the male and female study participants at admission are
presented in Table 2.
A number of 687 groin and nasal swabs were collected
to detect MRSA; overall positivity has been 5.24%, 4.72%
in male and 5.88% in female participants. If we compare
the positivity rates between the two sites, groin and nasal
cavity, they were 2.91% for the groin and 3.35 % for the
nasal. In the sameGram-positivemicroorganisms, our results
show a low rate of VRE colonization, less than 1%, slightly
higher in female patients (0.25% versus 0.59%). 162 from
1343 (12.06%) of the studied patients were colonized upon
admission with one or more of ESBL-producing organisms.
Among the colonizing organisms, 50.76% of the ESBL-
producing organisms belonged to the E. coli species. There
were no significant differences between males (11.96%) and
females (12.19%). Among Gram-negative bacteria with a
reduced susceptibility to most carbapenem agents (CRE),
Enterobacterales were the most prevalent (21.16%). In this
order, the principal colonizer organism was E. coli (68.07%),
followed by Enterobacter spp. (11.5%), Proteus spp. (7.04%),
and Klebsiella spp. (4.2%). Nonfermenters were identified as
Pseudomonas aeruginosa and Acinetobacter baumannii and
they are almost in the same proportion in males and females,
being less than 1% (11 from 1389).
3.3. Bacterial Pattern of Colonization at 7 Days. Patients who
were hospitalized formore than 7 dayswere retested using the
same nasal, groin, and rectal swabs for MRSA, VRE, ESBL,
and CRE infection (see Table 3).
According to our results, we found that more than 90%
of patients were admitted to the ICU without MRSA or VRE
infection regardless of gender. Approximately 3 to 4% of
patients acquired MRSA infection during the ICU stay, and
in male participants 2.99% were found with VRE positivity.
We tested the patients during the first day of admission to the
ICU and 4% of male and 7.69% of female patients were found
to be positive to MRSA upon admittance, and all of them
were found to be cleared of infection during the first week of
stay. Regarding ESBL and CRE, we found that approximately
88% arrived to the ICU without being colonized, but during
their first 7 days of hospitalization nearly 40% got infected
with ESBL, while regarding CRE this number is closer to 33%.
Upon admittance, 10-15% of patients were positive either to
CRE and/or ESBL, and only half of them were found to be
clear of infection during their first week of hospitalization.
3.4. Risk Factors for Colonization. According to our analysis,
there was no significant association between age, Carmeli’s
score, and any of the examined comorbidities regarding
MRSA or VRE infection upon admittance neither in male
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Table 2: Spectrum of bacterial colonization upon admission. MRSA-N: MRSA detected from nasal cavity; MRSA-G: MRSA detected from
groin area.
Male Female
Number of patients [n] Positivity [n] Positivity [%] Number of patients [n] Positivity [n] Positivity [%]
MRSA 381 18 4.72% 306 18 5.88%
MRSA-N 381 13 3.41% 306 10 3.26%
MRSA-G 381 9 2.36% 306 11 3.59%
VRE 400 1 0.25% 340 2 0.59%
ESBL 744 89 11.96% 599 73 12.19%
CRE 833 166 19.92% 556 127 22.84%
Table 3: Bacterial colonization of male and female patients upon 7 days of admission. NEG-NEG: no infection was found at admittance
and at 7 days. NEG-POS: no infection was found at admittance but the patient was found to be infected at 7 days. POS-NEG: infected at
admittance but no infection was found at 7 days. POS-POS: infected at admittance and the patient was found to be infected at 7 days.
Male Female
MRSA VRE ESBL CRE MRSA VRE ESBL CRE
NEG-NEG 93% 97.01% 52% 63.11% 88.46% 100% 49.66% 54.86%
NEG-POS 3% 2.99% 33.33% 25.41% 3.85% 0% 37.24% 32.64%
POS-NEG 4% 0% 6% 4.92% 7.69% 0% 6.90% 4.86%
POS-POS 0% 0% 8.67% 6.56% 0% 0% 6.21% 7.67%
Table 4: Analysis of risk factors related to bacterial infections upon ICU admission in male patients. OR: Odds Ratio; ∗: p<0.05; ∗∗: p<0.01;
∗∗∗: p<0.001.
Risk factor MRSA colonization VRE colonization
Present [n] Absent [n] OR P value Present [n] Absent [n] OR P value
Age > 65 years 10 208 0.9315 >0.9999 1 219 Infinity >0.9999
Carmeli’s score 10 161 1.568 0.4675 1 183 Infinity 0.46
Respiratory diseases 5 68 1.669 0.3575 0 67 0 >0.9999
Cardiovascular diseases 8 165 0.96 >0.9999 1 193 Infinity 0.485
Chronic renal failure 0 9 0 >0.9999 0 9 0 >0.9999
Chronic liver diseases 0 21 0 0.6123 0 20 0 >0.9999
Cancer 3 30 2.22 0.1972 0 34 0 >0.9999
Hematologic malignancy 0 1 0 >0.9999 0 2 0 >0.9999
Diabetes mellitus 4 53 1.671 0.3257 0 70 0 >0.9999
Risk factor ESBL colonization CRE colonization
Present [n] Absent [n] OR P value Present [n] Absent [n] OR P value
Age > 65 years 53 352 1.267 0.3101 87 312 1.334 0.1137
Carmeli’s score 46 273 1.497 0.0866 80 246 1.686 0.0039∗∗
Respiratory diseases 15 109 1.015 >0.9999 29 90 1.406 0.168
Cardiovascular diseases 32 312 0.6172 0.0415∗ 57 282 0.7463 0.1289
Chronic renal failure 6 10 4.663 0.0074∗∗ 7 14 2.117 0.156
Chronic liver diseases 12 20 4.948 0.0001∗∗∗ 12 21 2.474 0.022∗
Cancer 9 47 1.455 0.2914 18 51 1.518 0.1538
Hematologic malignancy 1 1 7.432 0.2251 0 2 0 >0.9999
Diabetes mellitus 12 104 0.8257 0.6422 28 90 1.347 0.2105
nor in female patients. In male patients chronic renal failure
and liver disease and in female patients only chronic renal
failure proved to be significant risk factors for acquiring
ESBL infection, with an approximately 5 times higher risk
compared to the rest of the participants. Contrarily, cardio-
vascular diseases in male patients seem to be posing a lower
risk of ESBL infection. Regarding CRE, Carmeli’s score and
chronic liver diseases in male patients, and chronic renal
failure in female patients represents a higher risk of infection,
while cardiovascular diseases in female participants show a
lower risk of colonization (see Tables 4 and 5).
The risk assessment of infection at 7 days showed statis-
tical significance for ESBL and CRE in both male and female
patients (see Table 6).
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Table 5: Analysis of risk factors related to bacterial infections upon ICU admission in female patients. OR: Odds Ratio;∗: p<0.05; ∗∗: p<0.01.
Risk factor MRSA colonization VRE colonization
Present [n] Absent [n] OR P value Present [n] Absent [n] OR P value
Age > 65 years 13 207 1.017 >0.9999 2 241 Infinity >0.9999
Carmeli score 9 166 0.7349 0.6254 2 189 Infinity 0.5062
Respiratory diseases 6 53 2.217 0.128 1 66 4.121 0.3558
Cardiovascular diseases 11 159 1.275 0.8077 1 176 0.9205 >0.9999
Chronic renal failure 0 4 0 >0.9999 0 5 0 >0.9999
Chronic liver diseases 1 7 2.361 0.3879 0 12 0 >0.9999
Cancer 2 24 1.375 0.6571 1 32 9.563 0.185
Hematologic malignancy - - - - - - - -
Diabetes mellitus 3 68 0.6471 0.7734 0 82 0 >0.9999
Risk factor ESBL colonization CRE colonization
Present [n] Absent [n] OR P value Present [n] Absent [n] OR P value
Age > 65 years 50 376 0.8673 0.5843 83 311 0.8217 0.4234
Carmeli score 44 288 1.254 0.3828 64 239 0.8879 0.6051
Respiratory diseases 9 81 0.7726 0.6011 28 74 1.44 0.1472
Cardiovascular diseases 35 277 0.8279 0.4564 49 238 0.5433 0.0038∗∗
Chronic renal failure 4 6 5.024 0.0241∗ 4 4 3.624 0.0754
Chronic liver diseases 3 15 1.46 0.472 6 12 1.809 0.2501
Cancer 8 37 1.627 0.2362 10 38 0.9246 >0.9999
Hematologic malignancy - - - - - - - -
Diabetes mellitus 19 118 1.217 0.5518 28 108 0.8921 0.7208
Table 6: Analysis of risk factors related to bacterial infections after 7 days. OR: Odds Ratio; ∗: p<0.05; ∗∗∗: p<0.001.
MRSA colonization VRE colonization
Present [n] Absent [n] OR P value Present [n] Absent [n] OR P value
Male 3 93 0.6505 0.7801 2 65 11.94 0.0553
Female 4 92 0.6957 0.6163 0 181 0 0.5457
ESBL colonization CRE colonization
Present [n] Absent [n] OR P value Present [n] Absent [n] OR P value
Male 50 78 4.79 <0.0001∗∗∗ 31 77 1.665 0.031∗
Female 54 72 5.404 <0.0001∗∗∗ 47 79 2.104 0.0006∗∗∗
4. Discussion
In this study, we have analysed the incidence and pat-
tern of bacterial colonization including MDR Gram-positive
(MRSA, VRE) and Gram-negative (ESBL, CRE) germs in
ICU patients upon admission and after 7 days. Multidrug
resistance in Enterobacterales and nonfermenting Gram-
negative bacilli represent a real challenge to the hospitals
or healthcare institutions. Carriage or infections with these
isolates can result in compromised treatment options and
high mortality rates in patients. Therefore, early detection
of infected or colonized patients is compulsory for the best
patient management and to prevent the patient-to-patient
transmission or environmental contamination. In addition,
identifying the risk factors associated with MDR bacterial
infections and the most commonly occurring MDR strains
may be of use to hospital antimicrobial drug management
and the prevention of nosocomial contamination [40]. Most
investigations of risk factors for multidrug-resistant strains
have been hospital-based and focused on them. The risk
factors can be exposure to antibiotics andmultidrug-resistant
strains in the environment (recent antibiotics and/or hospi-
talization, history of multidrug-resistant strains, colonization
pressure, comorbidity, and dialysis) and special conditions
that facilitate colonization and infection (illness severity,
wounds, indwelling devices, etc.). Some risk factors have
more importance than others, but they can be evaluated
and updated. The prevalence and patterns of resistance
vary significantly by geographical area, location, size, and
facility type, with each institution having a unique pattern.
Some hospitals screen all admissions for multidrug-resistant
strains colonization. Moreover, an important recommenda-
tion is to follow the guidelines regarding the prevention of
nosocomial infections. Our institution recently introduced
Carmeli’s score for evaluation of risk factors for infections
with resistant or multidrug-resistant bacteria and it allows
doing a prediction. A better diagnostic information includes
culture of the causative pathogen and the screening for them
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was performed only for one year (2017). Rising rates of Gram-
negativemultidrug-resistant bacteria have been documented.
Therefore, it is essential to collect these data andnot to assume
that our ICU issues are the same as those reported by others.
The overall MRSA carriage rate of 5.2% found in our
study is less than 22.5%, which was reported by Ray et al.
[41], and greater than 3%, as reported by other scientists
[42, 43]. The slightly higher prevalence of MRSA carriage
found in the present study could be explained by the relatively
small number of patients examined, and the significantly
higher rate of infection in Ray’s report could be due to the
multiple sites of sampling which could detect the presence
of MRSA with more accuracy. One of the most prevalent
sites of MRSA has been reported to be the nose and our
data is in agreement with that observation [41].The incidence
of MRSA infection in the ICU was nearly the same as that
on admission in the case of male patients, but females were
more likely to be affected on admission than being infected
in the hospital. We observed that the rate of MRSA erad-
ication during the hospitalization was 100%, which can be
attributed to the absence of correlation of the MRSA carriage
with different risk factors and to the correctly chosen and
applied antibiotic therapy. Previous studies have identified
various risk factors for VRE colonization including advanced
age, central venous catheterization, extended hospitalization,
haematologic malignancies, haemodialysis, exposure to mul-
tiple antibiotics, and prolonged duration of antibiotic therapy
[44]. Karki et al. in a study detected 17.5% prevalence of VRE
colonization on the day of screening [45]. Contrarily, our
results show a significantly low rate ofVRE colonization upon
admission (0.4%), which is slightly higher in female patients.
Seven days of ICU stay provednohigher risk ofVRE infection
regardless of gender. The beta-lactam antimicrobial agents
are among the most commonly used classes of antibiotics.
Consequently, resistance to 𝛽-lactams by production of 𝛽-
lactamases is the most common cause of resistance to these
drugs. Majority of the ESBLs are found in Klebsiella spp.
and Escherichia coli [46]. Our study results identified 12.06%
prevalence rate for ESBL producers and it correlates well
with data from an Iranian report but a Canadian research
group found less occurrence in their patient screening study
[47, 48]. Regarding ICU stay, we concluded that at least 7
days of admittance poses an approximately five times higher
risk of ESBL contamination. According to our results, chronic
renal failure and liver diseases might contribute to such high
prevalence; however, we also found that more than half of
the already ESBL-infected patients staying in the ICU were
still carrying the MDR strain after one week of hospital care.
As a subclass of beta-lactam antibiotics, the carbapenems
are usually applied as spare drugs in the treatment of severe
bacterial infections that are resistant to the commonly used
antibiotics. The current study showed very high incidence
(21.06%) of CRE infection and more in the female than male
patients at admission and after 7 days. Upon admittance,
more than 10% arrived already carrying the carbapenemase
expressing strain, and half of these colonizers were positive to
CRE after 7 days.They might have contributed to that during
the hospitalization; more than 30% of the CRE-negative
patients acquired CRE infection. Apart from hospitalization,
chronic liver diseases and Carmeli’s score proved to be a
statistically significant risk factor in men, while in the case
of women we found a tendency that points to the possible
connection of chronic renal failure to CRE infection.
According to our current results, we can report that
nosocomial infections can occur in the Intensive Care Unit
of Emergency Clinical County Hospital of Oradea. The
most common isolates were ESBL and CRE strains, but in
comparison Gram-positive MDR bacteria such as MRSA
and VRE were detected in a significantly less proportion.
It is promising that, in addition to the lower level of colo-
nization, MRSA and VRE were showing a better response
to antimicrobial therapy compared to GN MDR bacteria.
However, ESBL and CRE pose a difficult problem by either
medical or economic reasons.The number of nosocomial GN
infections was remarkably high, which can be attributed to
the fact that more than half of the originally infected patients
remain carriers even after being a week after admittance
into intensive care, and it should also be noted that the
hospital environment contributes to the selection of strains
displaying one or more resistance mechanisms against the
antibiotics; therefore we have to prepare for the appearance of
more persistent bacteria in the future.Wemust underline the
importance of rational antibiotic strategies, the appropriate
personal hygiene and preventive methods, and the consider-
ation of auxiliarymedical therapies, such as the application of
natural compounds that might offer favourable alternatives
based on their antioxidant and disinfectant properties [49,
50]. Finally, the risk factor assessment should be done before
selecting empiric antibiotic therapy and it could improve
the prognosis of some patients and help the development
of infection control policies and procedures, as well as the
review of antibiotic utilization and its relationship to local
antibiotic resistance patterns, together with the development
of guidelines for the rational use of antimicrobial therapy.
5. Conclusion
Our study is in accordance with other findings and supports
the importance of identifying and managing risk factors
involved in the mechanism of colonization of the human
patients with potentially multidrug-resistant pathogenic bac-
teria during hospitalization, especially in the intensive care
unit.
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